Cantor Fitzgerald设定的200美元目标价表明对英伟达股票持积极展望，反映了对公司战略及其克服当前障碍潜力的信任。即使英伟达面临除中国外尚未在国际上发货H20处理器的现实，该目标价仍得到维持。

Investing.com — 周一，Cantor Fitzgerald重申了对特斯拉 (NASDAQ: TSLA ...

智通财经APP获悉，金融服务机构Cantor Fitzgerald两位生物技术分析师乔希·希默和埃里克·施密特罕见地公开炮轰美国卫生部长肯尼迪的领导力，呼吁特朗普政府在美国食品和药物管理局 (FDA)疫苗主管彼得·马克斯被迫辞职后"重新评估这位部长的职位"。这份周一正午发布的报告措辞之严厉，在金融界引发轩然大波。

Eric Johnston, Cantor Fitzgerald chief equity & macro strategist, joins 'Closing Bell Overtime' to talk economic and market impact of tariffs.

Cantor Fitzgerald lowered the firm’s price target on Meta Platforms (META) to $624 from $790 and keeps an Overweight rating on the shares. The ...

Fintel reports that on April 15, 2025, Cantor Fitzgerald upgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from ...

On Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on Health Catalyst Inc. (NASDAQ:HCAT) with a steady price target of $16.00. According to InvestingPro data, this target represents ...

On Tuesday, Cantor Fitzgerald reiterated their Overweight rating on shares of Cidara Therapeutics (NASDAQ:CDTX), highlighting the potential of the company’s lead asset, CD388, as it approaches ...

Meeting to be held in Houston on April 15 hosted by Cantor Fitzgerald. Stay Ahead of the Market: Discover outperforming stocks and invest ...

Cantor Fitzgerald doubled down on its bearish stance toward stocks on Monday, reaffirming its negative outlook with the statement, “we continue to be bearish on equities” in an investor note ...

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at ...

Equities research analysts at Cantor Fitzgerald began coverage on shares of Okta (NASDAQ:OKTA – Get Free Report) in a report released on Monday, Marketbeat.com reports. The brokerage set an ...